BOJ keeps interest rates flat, but flags rate hikes on rising inflation, GDP
Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions Inc. (NASDAQ:BLFS), recently sold shares of the company. According to an SEC filing, Aebersold sold a total of 8,327 shares over two transactions, with a combined value of approximately $209,135. These transactions occurred on March 14 and March 17, 2025, with share prices ranging from $24.96 to $25.44. The stock, currently trading at $25.33, has shown remarkable strength with a 52.47% return over the past year, according to InvestingPro data.
Following these transactions, Aebersold holds 43,165 shares of BioLife Solutions. The sales were conducted under a Rule 10b5-1 trading plan, which was adopted in December 2024, as noted in the filing. InvestingPro analysis shows the company maintains a strong financial position with a healthy current ratio of 4.54 and conservative debt levels. Analysts maintain a bullish outlook, with price targets ranging from $30 to $34. Get access to 8 more exclusive ProTips and comprehensive analysis through InvestingPro’s detailed research report.
In other recent news, BioLife Solutions reported strong fourth-quarter results and issued optimistic guidance for 2025, capturing the attention of analysts and investors. The company announced a fourth-quarter revenue of $22.7 million, surpassing analyst estimates and marking a 31% year-over-year increase. BioLife’s Cell Processing segment, a key driver of growth, saw a 37% year-over-year revenue increase to $20.3 million. For the full year of 2024, BioLife reported total revenue of $82.3 million, excluding discontinued operations, and a net loss of $11.4 million, which was smaller than projected. Looking forward, BioLife anticipates total revenue for 2025 to range between $95.5 million and $99 million, reflecting a 16-20% year-over-year growth. Analysts from KeyBanc and H.C. Wainwright have shown confidence in the company’s prospects, with H.C. Wainwright raising the price target to $30 and maintaining a "Buy" rating. Benchmark also reiterated a "Buy" rating with a $30 target, noting BioLife’s better-than-expected financial performance. The company has completed divestitures of non-core assets to focus on its high-margin core business, which is now embedded in 17 approved cell and gene therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.